Q-omics provides the consensus-scored DDX20 profile across patient tissues and cancer cell-line models. DDX20 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DDX20 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, DDX20 protein abundance shows 27,956 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where DDX20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX20 survival associations across molecular data types. DDX20 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX20 RNA expression–survival associations across cancer types. High DDX20 expression shows unfavorable associations in ACC, LIHC and LGG, but favorable associations in READ, KIRC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DDX20 RNA expression.
This table summarizes DDX20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DDX20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX20 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, COAD and BLCA. The HNSC box plot shows higher DDX20 RNA expression in tumor versus normal tissue (log2 FC = +0.664, t-test p < 0.001).
This table shows molecular features associated with DDX20 in patient tissues and cancer cell lines. In patient samples, DDX20 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DDX20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
